Market Place
Sourcing Support
BENEV Company and Hugel Inc. announce Letybo® commercialization
25 Mar 2025 //
PR NEWSWIRE
FDA Issues Form 483 to Hugel, Inc.
23 Sep 2024 //
FDA
Hugel Receives FDA Approval in the United States of Letybo for Injection
04 Mar 2024 //
PR NEWSWIRE
Hugel Receives U.S. FDA Approval for Its Botulinum Toxin Letybo
03 Mar 2024 //
PR NEWSWIRE
Hugel`s `Letybo` First in Korea to Obtain Marketing Approval from Australia
24 Nov 2022 //
PRNEWSWIRE
Hugel resubmits BLA for botulinum toxin, Botulax to US FDA
08 Oct 2022 //
PHARMABIZ
Hugel Achieves Record-High Performance for 2Q…Revenue of KRW67.4bn
10 Aug 2022 //
PRESS RELEASE
Recent publication confirms the efficacy and safety of LetibotulinumtoxinA i
26 Jul 2022 //
PRESS RELEASE
Hugel accelerates the leap forward as a global company
19 May 2022 //
PRESS RELEASE
FDA Issues form 483 to Hugel Inc.
20 Aug 2021 //
FDA
Hugel America Announces U.S. FDA Acceptance of BLA for LetibotulinumtoxinA
15 Jun 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.